REG - ValiRx PLC - Update on proposed sub-license of VAL201

ValiRxAnnouncement

23/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW6771Fa&default-theme=true

RNS Number : 6771F  ValiRx PLC  23 March 2022

ValiRx PLC ("ValiRx" or the "Company")

Update on proposed sub-license of VAL201

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health today provides an update on
progress towards the completion of the proposed sub-license of VAL201 to
TheoremRx Inc ("TheoremRx").

As announced on 2 November 2021, ValiRx entered into a non-binding Letter of
Intent ("LOI") with TheoremRx for the sub-license of VAL201. The LOI has been
re-executed with an exclusivity period expiring before the end of June 2022.

TheoremRx reports that it continues to make good progress with its financing,
however current global macro-economic events have impacted the timelines.
Upon successful completion of the financing by TheoremRx, the first payments
to ValiRx under the sub-license are anticipated on or before end-June 2022.

The service agreement previously announced on 5 January 2022 has allowed
ValiRx to work closely with the TheoremRx Chief Scientific Officer,
identifying partners to conduct the next clinical trial of VAL201 in the UK.

The LOI and proposed Licence Agreement (as referred to in the announcement of
2 November 2021) therefore remain non-binding and there is no guarantee that
this Licence Agreement will be executed or that it will generate material
revenues within the expected timeframe or at all.

Dr Suzy Dilly, CEO of ValiRx commented: "Although the sub-license of VAL201
to TheoremRx has taken longer to complete than initially anticipated, during
the course of the past four months, ValiRx has been continuing to conduct due
diligence on TheoremRx and its scientific plans and remains confident that it
is well placed to conduct the ongoing development of the VAL201 programme.
Our due diligence procedures are now complete and during this final extension
of exclusivity we will continue to provide scientific support to TheoremRx's
trial start-up processes to ensure no further delays are encountered."

Dr Patrick Frankham, CEO of TheoremRx added: "Working with the ValiRx team
over the past few months has enabled us to commence building a relationship
which will ensure that VAL201 is progressed efficiently once the sub-license
is fully executed, but also ensured that the team we are building covers all
the required expertise and has a shared vision for the future of TheoremRx.
I am excited to be building the VAL201 project into our new pipeline of
oncology assets."

Dr Ken Sorensen, Chairman of TheoremRx stated: "The funding environment over
the past four months has been challenging, and although global destabilising
events, including the situation in Ukraine and the ongoing Covid pandemic,
should not directly impact our activities, we have found that investors are
taking extra precautions over their due diligence and taking longer than
typical to reach decisions. We have made positive progress towards securing
the desired funding to cover the breadth of our pipeline, and we remain highly
confident of success."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)    Tel: +44 (0) 20 7213 088

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities Limited (Broker)                  Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDJTMTTMTMTTFT